Parkman Healthcare Partners LLC Cuts Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Parkman Healthcare Partners LLC decreased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 21.1% during the third quarter, according to its most recent filing with the SEC. The firm owned 903,140 shares of the biopharmaceutical company's stock after selling 241,506 shares during the period. Parkman Healthcare Partners LLC owned 0.46% of Esperion Therapeutics worth $1,490,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Wasatch Advisors LP increased its position in Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company's stock valued at $23,655,000 after buying an additional 3,688,796 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock valued at $9,554,000 after buying an additional 2,087,635 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Esperion Therapeutics by 71.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company's stock valued at $1,174,000 after buying an additional 295,378 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Esperion Therapeutics by 3,278.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company's stock valued at $1,271,000 after buying an additional 555,382 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Price Performance

ESPR traded up $0.41 during trading on Wednesday, reaching $3.66. 10,909,680 shares of the company's stock were exchanged, compared to its average volume of 6,177,678. Esperion Therapeutics, Inc. has a 1 year low of $1.35 and a 1 year high of $3.81. The stock has a market capitalization of $721.15 million, a P/E ratio of -5.41 and a beta of 1.01. The company's fifty day simple moving average is $2.18 and its 200-day simple moving average is $2.17.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Needham & Company LLC lowered their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, August 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.